Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study. (Q51286470)

From Wikidata

Jump to navigation Jump to search

scientific article published in December 2016

Language	Label	Description	Also known as
English	Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study.	scientific article published in December 2016

Statements

scholarly article

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/27916408

Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study. (English)

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/27916408

1 reference

based on heuristic

inferred from title

Staphylococcus aureus

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/27916408

William C. Gruber

14

object named as

William C Gruber

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/27916408

13

object named as

Kathrin U Jansen

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/27916408

Clarence Buddy Creech

2

object named as

C Buddy Creech

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/27916408

author name string

Robert W Frenck

1

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/27916408

David J Seiden

4

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/27916408

Martin K Kankam

5

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/27916408

James Baber

6

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/27916408

Edward Zito

7

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/27916408

Robin Hubler

8

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/27916408

Joseph Eiden

9

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/27916408

Joseph M Severs

10

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/27916408

Shite Sebastian

11

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/27916408

Jasdeep Nanra

12

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/27916408

Annaliesa S Anderson

15

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/27916408

Douglas Girgenti

16

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/27916408

language of work or name

0 references

publication date

1 December 2016

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/27916408

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/27916408

35

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/27916408

2

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/27916408

375-384

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/27916408

Clinical features and outcome of Staphylococcus aureus infection in elderly versus younger adult patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

Staphylococcus aureus infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

Demonstration of the preclinical correlate of protection for Staphylococcus aureus clumping factor A in a murine model of infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

Clinical identifiers of complicated Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

Host-imposed manganese starvation of invading pathogens: two routes to the same destination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

Regulation of Staphylococcus aureus MntC expression and its role in response to oxidative stress

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

Staphylococcus aureus manganese transport protein C is a highly conserved cell surface protein that elicits protective immunity against S. aureus and Staphylococcus epidermidis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

Challenges for the evaluation of Staphylococcus aureus protein based vaccines: monitoring antigenic diversity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

Evaluation of approaches to monitor Staphylococcus aureus virulence factor expression during human disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

Cocoon abdomen - A rare cause of intestinal obstruction

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus colonization and infection among infants at a level III neonatal intensive care unit

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

Leukocytic function in hypogammaglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

Variation in the type and frequency of postoperative invasive Staphylococcus aureus infections according to type of surgical procedure.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

Postoperative Staphylococcus aureus infections in Medicare beneficiaries

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

Vaccine review: "Staphyloccocus aureus vaccines: problems and prospects".

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

Surgical site infections after abdominal surgery: incidence and risk factors. A prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.010

7 January 2021

Identifiers

10.1016/J.VACCINE.2016.11.010

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/27916408

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/27916408

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51286470&oldid=1784484966"